{"id":881546,"date":"2025-09-03T12:21:59","date_gmt":"2025-09-03T16:21:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\/"},"modified":"2025-09-03T12:21:59","modified_gmt":"2025-09-03T16:21:59","slug":"outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\/","title":{"rendered":"Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ISELIN, N.J., Sept.  03, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DLhr0JAUazTHmNQ8J7GtctWa5n-Ahs2So7nb8lqMLEKNPdglzUaW_YZX0jFhJgMu4IReEE6fMF1V8xGAH_jWhUtNQnHZZbUzMiKhQWrAxw0CE3v2ZakjVo7qH4MCgTDz\" rel=\"nofollow\" target=\"_blank\">Outlook Therapeutics, Inc.<\/a> (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=I_1d5DCSPnkYOIO8i6x_SrHWJLu8DbttExr2vwJbc_kLRh8pVTiZQ9iMccVrq0LmcAX0Bz9g7w6_bi9PMwMlIBiWuC_sq7OU9FRN2V79hC677L_KoQ6PAreY3It--jLA\" rel=\"nofollow\" target=\"_blank\">EURETINA Innovation Spotlight<\/a> being held as part of the 25<sup>th<\/sup> EURETINA Congress on September 3, 2025 in Le Palais des Congr\u00e8s, Paris.<\/p>\n<p align=\"justify\">Details for the presentations are as follows:<\/p>\n<p align=\"justify\">\n        <strong>Session:<\/strong> VEGF Related and Other Retinal Indications <br \/><strong>Title: <\/strong><em>Optimising the treatment of retinal disease<\/em><br \/><strong>Presenter<\/strong><strong>:<\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JG9yzNoIXCLz4Opuw4EB64mBBas9za_df56NhHdUS3u5OeFPgp6t_sr9sqL8H87zZam2y9cT-ssSvBv8I2nVgbCAAj6BUB7y14AR5EsxlBTs9d1zJWjHZFjjDWE75aop6T7AuWhT3Gf073nNiV7T0GM7kU9P1cu3HVPVIlt4ZdE=\" rel=\"nofollow\" target=\"_blank\">Bob Jahr, Chief Executive Officer<\/a> of Outlook Therapeutics<br \/><strong>Date and Time:<\/strong> Wednesday, September 3, 2025, 16:10 PM CEST \/ 10:10 AM EDT<\/p>\n<p align=\"justify\">For more information about this event, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-FP8bY3O5XQV1cOvzy4vHwu_CMwZnvizaFUIv1zUnx8Nm7qJkGStxgad9pXEajJQxA6UxyRHghZknOVodWhcfWA7u3rzNB9-vHyzsVTBrbs=\" rel=\"nofollow\" target=\"_blank\">EIS 2025<\/a>.<\/p>\n<p>\n        <strong>About Outlook Therapeutics, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010\/LYTENAVA\u2122 (bevacizumab-vikg, bevacizumab gamma) to optimize the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA\u2122 (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA\u2122 (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD.<\/p>\n<p align=\"justify\">In the United States, ONS-5010\/LYTENAVA\u2122 (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010\/LYTENAVA\u2122, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.<\/p>\n<p>\n        <strong>Investor Inquiries:<br \/><\/strong>Jenene Thomas<br \/>Chief Executive Officer<br \/>JTC Team, LLC<br \/>T: 908.824.0775<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EvP-HJzzK4x1TvMQv0wsAO8FJxiIgGLy6owqVTZGE0H9EqcNEnsBf-EhqNJf3swXyjHnjCRgCCpryG-xrt3PmQ==\" rel=\"nofollow\" target=\"_blank\">OTLK@jtcir.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjUwNCM3MTI3MTAxIzIwMjg4MjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MTA0MTBlZDAtNmE5ZS00YTM4LWFlZTUtYWU3MjU3NTY4NmNjLTEwNDAzOTMtMjAyNS0wOS0wMy1lbg==\/tiny\/Outlook-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) &#8212; Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the EURETINA Innovation Spotlight being held as part of the 25th EURETINA Congress on September 3, 2025 in Le Palais des Congr\u00e8s, Paris. Details for the presentations are as follows: Session: VEGF Related and Other Retinal Indications Title: Optimising the treatment of retinal diseasePresenter:Bob Jahr, Chief Executive Officer of Outlook TherapeuticsDate and Time: Wednesday, September 3, 2025, 16:10 PM CEST \/ 10:10 AM EDT For more information about this event, please visit EIS 2025. About Outlook Therapeutics, Inc. Outlook Therapeutics is a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-881546","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) &#8212; Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the EURETINA Innovation Spotlight being held as part of the 25th EURETINA Congress on September 3, 2025 in Le Palais des Congr\u00e8s, Paris. Details for the presentations are as follows: Session: VEGF Related and Other Retinal Indications Title: Optimising the treatment of retinal diseasePresenter:Bob Jahr, Chief Executive Officer of Outlook TherapeuticsDate and Time: Wednesday, September 3, 2025, 16:10 PM CEST \/ 10:10 AM EDT For more information about this event, please visit EIS 2025. About Outlook Therapeutics, Inc. Outlook Therapeutics is a &hellip; Continue reading &quot;Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-03T16:21:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjUwNCM3MTI3MTAxIzIwMjg4MjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)\",\"datePublished\":\"2025-09-03T16:21:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\\\/\"},\"wordCount\":242,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjUwNCM3MTI3MTAxIzIwMjg4MjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\\\/\",\"name\":\"Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjUwNCM3MTI3MTAxIzIwMjg4MjI=\",\"datePublished\":\"2025-09-03T16:21:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjUwNCM3MTI3MTAxIzIwMjg4MjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjUwNCM3MTI3MTAxIzIwMjg4MjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\/","og_locale":"en_US","og_type":"article","og_title":"Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) - Market Newsdesk","og_description":"ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) &#8212; Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the EURETINA Innovation Spotlight being held as part of the 25th EURETINA Congress on September 3, 2025 in Le Palais des Congr\u00e8s, Paris. Details for the presentations are as follows: Session: VEGF Related and Other Retinal Indications Title: Optimising the treatment of retinal diseasePresenter:Bob Jahr, Chief Executive Officer of Outlook TherapeuticsDate and Time: Wednesday, September 3, 2025, 16:10 PM CEST \/ 10:10 AM EDT For more information about this event, please visit EIS 2025. About Outlook Therapeutics, Inc. Outlook Therapeutics is a &hellip; Continue reading \"Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-03T16:21:59+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjUwNCM3MTI3MTAxIzIwMjg4MjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)","datePublished":"2025-09-03T16:21:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\/"},"wordCount":242,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjUwNCM3MTI3MTAxIzIwMjg4MjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\/","name":"Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjUwNCM3MTI3MTAxIzIwMjg4MjI=","datePublished":"2025-09-03T16:21:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjUwNCM3MTI3MTAxIzIwMjg4MjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjUwNCM3MTI3MTAxIzIwMjg4MjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-spotlight-eis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=881546"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881546\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=881546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=881546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=881546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}